BAY 50-4798

BAY 50-4798 is a **recombinant interleukin-2 (IL-2) analogue** engineered to selectively activate **T cells** over **natural killer (NK) cells** by increasing specificity for the high-affinity IL-2 receptor (CD25) on T cells. It contains a single amino acid substitution (arginine for asparagine at position 88) that greatly increases selectivity, resulting in up to 3,000-fold higher activity for T cells compared to NK cells than wild-type IL-2[1][2][5]. This design aimed to **reduce the severe toxicity** associated with standard IL-2 (aldesleukin) therapy by minimizing activation of NK cells, while maintaining or improving therapeutic effects on cancer or immune diseases[1][2][3][5]. Developed by Bayer, BAY 50-4798 was investigated in phase I trials for metastatic renal cell carcinoma and melanoma, as well as in immune modulation settings such as HIV infection[1][2][5].

Other names

Interleukin-2 SAInterleukin2 SAInterleukin 2 SArecombinant interleukin-2 analog